GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. GLP-1 receptor agonists mimic this hormone at much higher concentrations — dramatically slowing how fast your stomach empties, sending powerful "I'm full" signals to your brain, and reducing the reward response to food. The result is a sustained reduction in calorie intake without the deprivation feeling of traditional dieting. Most patients report that food "noise" — constant thoughts about eating — decreases significantly within the first few weeks.

Semaglutide activates only GLP-1 receptors. Tirzepatide (referenced by brand names Mounjaro® and Zepbound®) activates both GLP-1 and GIP receptors — making it a dual agonist. Clinical trials show tirzepatide produces greater average weight loss (up to 22.5% of body weight vs. ~15% for semaglutide), though both are highly effective. Your provider will recommend the right option based on your health history, goals, and response to treatment.

The most common side effects are gastrointestinal — nausea, mild vomiting, constipation, and diarrhea — and are most common during the early titration phase. These typically resolve within 4–8 weeks as your body adjusts. Our gradual titration protocol is specifically designed to minimize these effects. Serious side effects are rare but include pancreatitis, gallbladder disease, and in animal studies, thyroid C-cell tumors (the clinical significance in humans is unknown). Your provider will review all risks in detail during your consultation.

Most patients notice reduced appetite within the first 1–2 weeks. Measurable weight loss typically begins by weeks 4–6, with the most significant results occurring between months 3–9 as doses reach their therapeutic level. Clinical trials ran for 68–72 weeks, and weight loss continues over that entire period. We recommend thinking of GLP-1 therapy as a 6–12 month program, not a quick fix — though many patients feel different within the very first month.

GLP-1 therapy works best when paired with a reduced-calorie, protein-rich diet and regular movement — though many patients find these habits become far easier on the medication since hunger and cravings diminish substantially. We don't prescribe restrictive diets. We provide nutritional guidance focused on preserving lean muscle mass and supporting sustainable weight loss. Strength training is particularly important on GLP-1 to ensure the weight you lose comes from fat, not muscle.

Most clinical trials show that stopping GLP-1 therapy leads to partial weight regain, typically 50–66% of lost weight over 1–2 years. This is because obesity is a chronic, hormonal condition — not a character flaw or discipline issue. Many patients choose to continue at a maintenance dose long-term. Your provider will work with you on a strategy — whether that means continuing, tapering, or transitioning to lifestyle maintenance — based on your individual goals and response.

Brand-name GLP-1 medications (Wegovy®, Zepbound®) may be covered by some insurance plans, particularly for patients with qualifying diagnoses. However, the compounded semaglutide and tirzepatide offered through many med spas (including ours) are typically not covered by insurance. Our transparent monthly pricing is designed to make these programs accessible. We can provide documentation for FSA/HSA reimbursement requests where applicable.